Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Neurocrine Biosciences (NBIX) has announced its participation in two major investor conferences this March. The company's leadership team will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, in Boston, and the Leerink Global Healthcare Conference on March 11, 2025, in Miami.
The presentations will be accessible via live webcasts on the company's investor relations website, with replays available for approximately one month after the events. Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company specializing in treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio includes FDA-approved treatments for conditions such as tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids.
Neurocrine Biosciences (NBIX) ha annunciato la sua partecipazione a due importanti conferenze per investitori questo marzo. Il team di leadership dell'azienda presenterà alla 45ª Conferenza Annuale sulla Salute di TD Cowen il 4 marzo 2025 a Boston, e alla Conferenza Globale sulla Salute di Leerink l'11 marzo 2025 a Miami.
Le presentazioni saranno accessibili tramite webcast dal vivo sul sito web delle relazioni con gli investitori dell'azienda, con riproduzioni disponibili per circa un mese dopo gli eventi. Neurocrine Biosciences è un'azienda biofarmaceutica focalizzata sulle neuroscienze, specializzata in trattamenti per disturbi neurologici, neuroendocrini e neuropsichiatrici. Il loro portafoglio include trattamenti approvati dalla FDA per condizioni come la discinesia tardiva, la corea di Huntington, l'iperplasia surrenalica congenita, l'endometriosi e i fibromi uterini.
Neurocrine Biosciences (NBIX) ha anunciado su participación en dos importantes conferencias para inversores este marzo. El equipo de liderazgo de la empresa presentará en la 45ª Conferencia Anual de Salud de TD Cowen el 4 de marzo de 2025 en Boston, y en la Conferencia Global de Salud de Leerink el 11 de marzo de 2025 en Miami.
Las presentaciones estarán disponibles a través de transmisiones web en vivo en el sitio web de relaciones con inversores de la empresa, con repeticiones disponibles durante aproximadamente un mes después de los eventos. Neurocrine Biosciences es una empresa biofarmacéutica centrada en las neurociencias, especializada en tratamientos para trastornos neurológicos, neuroendocrinos y neuropsiquiátricos. Su cartera incluye tratamientos aprobados por la FDA para condiciones como la discinesia tardiva, la corea de Huntington, la hiperplasia suprarrenal congénita, la endometriosis y los fibromas uterinos.
Neurocrine Biosciences (NBIX)는 이번 3월 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다. 회사의 리더십 팀은 2025년 3월 4일 보스턴에서 열리는 TD Cowen 제45회 연례 건강 관리 회의와 2025년 3월 11일 마이애미에서 열리는 Leerink 글로벌 건강 관리 회의에서 발표할 예정입니다.
발표는 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트로 접근 가능하며, 이벤트 후 약 한 달간 재생할 수 있습니다. Neurocrine Biosciences는 신경과학에 중점을 둔 생물 제약 회사로, 신경학적, 신경내분비 및 신경정신적 장애에 대한 치료법을 전문으로 합니다. 그들의 포트폴리오는 지연성 운동장애, 헌팅턴병 무도병, 선천성 부신 과형성, 자궁내막증 및 자궁 섬유종과 같은 질환에 대해 FDA 승인을 받은 치료제를 포함하고 있습니다.
Neurocrine Biosciences (NBIX) a annoncé sa participation à deux grandes conférences pour investisseurs ce mois de mars. L'équipe de direction de l'entreprise présentera à la 45e Conférence Annuelle sur la Santé de TD Cowen le 4 mars 2025 à Boston, et à la Conférence Mondiale sur la Santé de Leerink le 11 mars 2025 à Miami.
Les présentations seront accessibles via des webcasts en direct sur le site web des relations avec les investisseurs de l'entreprise, avec des rediffusions disponibles pendant environ un mois après les événements. Neurocrine Biosciences est une entreprise biopharmaceutique axée sur les neurosciences, spécialisée dans les traitements des troubles neurologiques, neuroendocriniens et neuropsychiatriques. Leur portefeuille comprend des traitements approuvés par la FDA pour des conditions telles que la dyskinésie tardive, la chorée de Huntington, l'hyperplasie surrénalienne congénitale, l'endométriose et les fibromes utérins.
Neurocrine Biosciences (NBIX) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im März bekannt gegeben. Das Führungsteam des Unternehmens wird am 4. März 2025 auf der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston und am 11. März 2025 auf der Leerink Global Healthcare Conference in Miami präsentieren.
Die Präsentationen werden über Live-Webcasts auf der Investor-Relations-Website des Unternehmens zugänglich sein, mit Wiederholungen, die etwa einen Monat nach den Veranstaltungen verfügbar sind. Neurocrine Biosciences ist ein biopharmazeutisches Unternehmen, das sich auf Neurowissenschaften konzentriert und auf die Behandlung von neurologischen, neuroendokrinen und neuropsychiatrischen Erkrankungen spezialisiert ist. Ihr Portfolio umfasst von der FDA zugelassene Behandlungen für Erkrankungen wie tardive Dyskinesie, Chorea Huntington, kongenitale Nebennierenhyperplasie, Endometriose und Uterusmyome.
- None.
- None.
- Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Chief Commercial Officer Eric Benevich will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:10 AM Eastern Time in
Boston . - Chief Financial Officer Matt Abernethy and Vice-President of Investor Relations Todd Tushla will present at the Leerink Global Healthcare Conference on Tuesday, March 11, 2025 at 11:20 AM Eastern Time in
Miami .
The live webcasts can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes
(*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-march-302385110.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When and where will Neurocrine Biosciences (NBIX) present at investor conferences in March 2025?
How can investors access NBIX's March 2025 conference presentations?
Which executives will represent NBIX at the TD Cowen Healthcare Conference 2025?
What are the main FDA-approved treatments in NBIX's current portfolio?
Which therapeutic areas does NBIX focus on for drug development?
